Life Sciences
Life Sciences: The Latest
  • EU Highlights
  • Viewpoints

Dutch urge greater Europe-wide action on antimicrobial resistance

Doctors and farmers need to use antibiotics less and more wisely, says Dutch health minister

Vaccine race underway for Zika virus

Following stark warnings from the World Health Organization, the rapid development of a vaccine has become a top priority

Non-profit alliance aims to advance treatments for rare diseases

The BioPontis Alliance hopes its new model for bringing patients’ insights and industry expertise to bear in preclinical research will reduce risk and promote development of rare disease therapies. The Alliance has funding from a Belgian charity for its first project

New reward system needed to encourage pharma to develop new antibiotics

As the first World Antibiotics Awareness week has highlighted, the traditional business model for antibiotics is broken. Incentives are required to promote development of new products, says Luke Moore. What about a lump sum payment?

Don’t let new EU medical devices bill restrict access to genetic tests

Irish geneticist David Barton adds his voice to leading research and patient groups across Europe who say proposed new regulations will create unworkable obstacles to DNA testing

How to fix Horizon 2020’s disheartening success rate

One of the best features of Horizon 2020 risks becoming its fatal flaw. Open-ended competitions have resulted in a flood of doomed applications, some 80 pages in length. Proposals should be shorter, and call topics tightened

Life Sciences Archive
Dutch urge greater Europe-wide action on antimicrobial resistance
Doctors and farmers need to use antibiotics less and more wisely, says Dutch health minister
Vaccine race underway for Zika virus
Following stark warnings from the World Health Organization, the rapid development of a vaccine has become a top priority
Cambridge joins consortium to launch £40M Apollo Therapeutics Fund
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and...
King's signs agreement with Pfizer in field of gene therapy
King’s College London has announced that it has recently entered into an exclusive license agreement with Pfizer Inc. for the development...
Non-profit alliance aims to advance treatments for rare diseases
The BioPontis Alliance hopes its new model for bringing patients’ insights and industry expertise to bear in preclinical research will reduce...
Page 1 of 696> 1 2 3  ... 
Innovation in Progress - Science|Business Network

Cambridge joins consortium to launch £40M Apollo Therapeutics Fund

Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40M to create the Apollo Therapeutics Fund

King's signs agreement with Pfizer in field of gene therapy

King’s College London has announced that it has recently entered into an exclusive license agreement with Pfizer Inc. for the development of a series of adeno-associated virus (AAV) gene therapy vectors

New role for motor neurons discovered at Karolinska

A new study presented in the journal Nature could change the view of the role of motor neurons

Horizon 2020 Special Coverage
Unlocking the value of Personalised Healthcare in Europe
This new study shows ICT investments could cut healthcare costs for key ailments by more than 35%.
Bigger and Simpler: A short guide to the EU's €80 billion Horizon 2020 programme
A two-year political fight formally began in Brussels on 30 November with the publication of the European Commission's plan for Horizon 2020, its omnibus R&D programme. It promises less red tape, broader benefits, and more jobs and economic growth.
Biofuels: The Next Generation
Key ideas and recommendations to accelerate the deployment of sustainable biofuels have emerged at the second in a series of three high-level academic policy debates on the energy R&D challenge, The Energy Difference
Advertisement